posted
I have seem some other boards here with a lot of member in it , and the PPS of the stock don't even move to a 50% up for a cheap profit, i wont say no stocks names but if you been watching you would know .
posted
Our day is coming again fellas don't listen to any basher or negitive person we have the only safe treatment for scd and more drugs in the pipe line and that is a fact and no pump.
If we hold we will all be greatly rewarded this can't be held back forever I have taken a lot of time from the computer and I will take more if need be but I won't sell at any where near these levels. glta
IP: Logged |
Our annual stockholders' meeting will be held on October 24, 2006, at 10:00 a.m. eastern daylight savings time, at our corporate headquarters at the New Brunswick Technology Center, 100 Jersey Avenue, Building B, Suite 310, New Brunswick, New Jersey 08901. At our annual meeting, we will ask you to:
o elect three nominees as directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified;
o ratify the selection of Moore Stephens, P.C. as our independent registered public accounting firm for 2006;
o approve the adoption of the 2006 Stock Award Plan authorizing the grant of options to purchase 150,000,000 shares of our common stock;
o approve an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock from 1,950,000,000 to 5,000,000,000, and
o transact any other business that may be properly presented at the annual meeting.
If you were a stockholder of record at the close of business on September 12, 2006, you may vote in person at the annual meeting and any postponements or adjournments of the meeting. A list of these stockholders will be available at our offices before the annual meeting.
Please sign, date and promptly return the enclosed proxy card in the enclosed envelope, so that your shares will be represented whether or not you attend the annual meeting.
posted
approve an amendment to our certificate of incorporation to increase the number of authorized shares of our common stock from 1,950,000,000 to 5,000,000,000, and
this doesnt look good 5 billion 0/s no way.
IP: Logged |
posted
No worries IMO...If they need the extra 3+ bil AS then that's fine...I want full production as soon as possible no matter what that takes...If increasing the AS will help us stay on schedule then have at it...IMO
IP: Logged |
posted
Not looking good ... 5 Billion shares they want? Shouldn't the sales of Nic. give them enuff capital to build whatever they need? So it takes a year or so to get that capital from the sales... better than diluting our shares
Ohh well... guess I am holding even longer now. Bah
IP: Logged |
posted
Nigeria introduces two sickle cell drugs at WHO summit From Collins Olayinka, Addis Ababa, Ethiopia NIGERIA yesterday received a rousing ovation from the rest of the African continent when she presented two locally manufactured drugs for sickle cell anaemia to the World Health Organisation (WHO) Regional Committee Meeting in Addis Ababa, Ethiopia.
This came two days after she faced international embarrassment for her alleged inability to halt the spread of the polio virus.
The two drugs the country introduced to the 56th session of the WHO meeting are Nicosan and Sikilafit. Both drugs are manufactured by Nigerian indigenous companies.
The country's Health Minister, Prof. Eyitayo Lambo, who presented the drugs to the international community ascribed them to the determination to look inward for a solution which was influenced by the fact that between four and five million Nigerians are still bearing the burden of sickle cell anaemia.
"Sickle cell disease is said to affect between four and five million Nigerians with a great number of people carrying the traits. This makes Nigeria the country with probably the greatest burden," he added.
He explained: "The National Institute for Pharmaceutical Research and Development (NIPRD) has developed a phyto-medicine product for the management of the disease. The recipe for the drug was obtained from a traditional medicine practitioner.
"The research institute first used the product in the original form in which the traditional medical practitioner provided it and made an assessment of its invitro anti-sickling properties that showed that the preparation possessed the ability to reduce the sickling tendency of red blood cells.
"The research institute then carried out many years of study on the plant materials to determine the right method of extraction and the preparation. Later, the relative quantities of the ingredients were adjusted in various studies in order to optimise pharmacological activities, materials and production processes," he explained further.
The health minister stressed that various stages of clinical trials were performed in humans to demonstrate the safety and efficacy of the drug and that clinical observations showed that Nicosan (the drug) is very effective in the management of sickle cell disease.
Lambo added that the drug was launched last month by President Olusegun Obasanjo and it was being produced locally for the Nigerian and West African market, adding that the manufacturers of the drug-Xechem Nig. Ltd had obtained an orphan drug status for the drug in the United States (U.S.).
He further disclosed that traditional medicine practitioners in Nigeria were making giant strides as they had produced another drug called Siklafit.
Siklafit is manufactured and marketed by Neimeth Nig. Ltd, another pharmaceutical company in Nigeria.
"Research in NIPRD has shown that other recipes brought in by traditional healers may be equally very effective when Research and Development (R&D) on them are completed," the Minister said yesterday.
Lambo declared that from the country's experience, it was believed that public-private partnership aimed at supporting basic and transnational research would produce more therapeutic agents from African /Traditional medicines for the management of sickle cell disease.
He, however, advised governments in the region, international donors and United Nations (UN) agencies particularly WHO to see sickle cell as a neglected disease whose management would require effective partnership. The partnership, he maintained, would be between researchers and donor agencies/ governments, stressing that there was the need to mobilize adequate funds for basic and applied research in the area.
South Africa and Uganda delegates specifically paid glowing tributes to Nigeria for the feat. But they also urged the country to do more in the area of research and also extend such efforts to effectively checkmating malaria, which is described as a disease that is more synonymous with the African continent.
The sickle cell anaemia is generally referred to as the Black man's disease because of its preponderance among people of African origin.
It is believed to have been wiped off or checkmated in Europe and other developed economies but the scourge still afflicts the African continent, bringing pain and sorrow to millions.
Lambo also told the gathering that the Nigerian government has so far established 185 HIV counseling sites, 235 Prevention of Mother To Child Transmission (PMTCT) and 115 Antiretroviral Therapy sites to halt the spread of the deadly HIV/AIDS in the country.
"Again, almost 100,000 patients are on treatment free of charge with the plan to scale up to at least 150,000 by the end of this year and 300,000 by the end of next year. We are looking into subsidising patients who are on ART since the cost to them is still prohibitive and this affects compliance and treatment," he explained.
He further disclosed that most positive pregnant women receive free ante-natal as well as six weeks post-natal care after delivery at all the Federal Government facilities. He added that Nigeria is also adopting a community-based approach in its HIV/AIDS programmes.
Lambo disclosed that eight drug manufacturers have begun local manufacturing of antiretroviral drugs locally.
On the low level of immunisation in Nigeria, the health minister said a series of steps have been taken to redress the situation.
One of these, according to him, is the adoption of a strategic plan on strengthening routine immunisation 2006-2009, which is in line with the Global Immunisation Vision and Strategy (GIVS).
Statistics, he said, have revealed that immunisation has increased from 37.5 per cent in December 2005 to 50 per cent by June 2006 and that government has set 65 per cent target by the end of 2006.
He also said measles morbidity and mortality have decreased in the three Northern zones following the December 2005 accelerated measles campaign which is also planned for the three Southern zones from October 3 to 9, 2006 with free distribution of insecticide treated nets as one of the major components that is expected to accompany the campaign.
He, therefore, solicited more technical and funding support from WHO and other development partners, especially in the areas of vaccines, logistics management, injection safety, data management/monitoring and evaluation.
BUSINESS SERVICES Property Appointments Money Watch Market Report Capital Market Business Travels Maritime Watch Industry Watch Energy Report Insurance Compulife
? 2003 - 2006 * Guardian Newspapers Limited (All Rights Reserved). Powered by dnetsystems.net dnet?
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Cool]](cool.gif)
![[Frown]](frown.gif)
![[Razz]](tongue.gif)
